| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.7326/0003-4819-112-9-682 |
| P698 | PubMed publication ID | 2110431 |
| P2093 | author name string | Love PE | |
| Santoro SA | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| anticoagulation | Q63279445 | ||
| antibody | Q79460 | ||
| P304 | page(s) | 682-698 | |
| P577 | publication date | 1990-05-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance | |
| P478 | volume | 112 |
| Q37637787 | A Case of "Refractory" Neuropsychiatric Lupus Responsive to Anticoagulation |
| Q33491733 | A case of cerebral infarction associated with positive antiphospholipid antibody in a systemic lupus patient |
| Q71502460 | A decrease in antiphospholipid antibodies before a thrombotic event |
| Q33487561 | A family study of anticardiolipin antibodies and associated clinical conditions |
| Q44011043 | A new lupus anticoagulant neutralization test based on platelet-derived vesicles |
| Q28207774 | A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection |
| Q41647250 | A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus |
| Q40358418 | A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). |
| Q36951385 | A review of neurological sequelae and cognitive deficits associated with antiphospholipid antibodies |
| Q40807893 | A review of the hypercoagulable state. |
| Q48373517 | A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? |
| Q39465272 | Abnormal IgG cardiolipin antibody titers in patients with Raynaud's phenomenon and/or related disorders: prevalence and clinical significance |
| Q40868635 | Abnormalities of hemostasis in ischemic stroke. |
| Q57437612 | Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus |
| Q33488617 | Activation of cultured vascular endothelial cells by antiphospholipid antibodies. |
| Q73089036 | Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant |
| Q90377963 | Acute myocardial infarction due to antiphospholipid antibody syndrome in a young pregnant woman |
| Q54506325 | Adamantiades-Behçet's disease, deep venous thrombosis and anticardiolipin antibodies: report of two cases. |
| Q48466057 | Alterations of cerebral blood flow and antiphospholipid antibodies in patients with systemic lupus erythematosus |
| Q80738558 | An abdominal pain syndrome in a lupus patient |
| Q43143079 | An antibody profile of systemic lupus erythematosus detected by antigen microarray |
| Q47825982 | An investigation in the possible effect of chronic headache on neuropsychological function in aCL-negative patients with SLE. |
| Q35867670 | Anaesthesia and the antiphospholipid syndrome: a review of 20 obstetric patients |
| Q73873107 | Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome |
| Q33344042 | Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome |
| Q33336296 | Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures |
| Q77373453 | Anti-cardiolipin antibodies in patients with inflammatory bowel disease |
| Q33493748 | Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation |
| Q52979605 | Anti-phospholipid antibodies and CD5+ B cells in HIV infection. |
| Q40467271 | Anti-β2-Glycoprotein I antibodies and thrombosis |
| Q48819631 | Antibodies Against Central Nervous System Tissue (Anti-Cns) Detected by Elisa and Western Blotting: Marker Antibodies for Neuropsychiatric Manifestations in Connective Tissue Diseases |
| Q28290536 | Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus |
| Q77697679 | Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis |
| Q47784251 | Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus |
| Q47702901 | Antibody specificity and related clinical features in antiphospholipid syndrome |
| Q53325327 | Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. |
| Q33331408 | Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. |
| Q33328447 | Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards |
| Q71691168 | Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study |
| Q71809483 | Anticardiolipin antibodies and antiphospholipid syndrome in chronic discoid lupus erythematosus |
| Q55365972 | Anticardiolipin antibodies and cardiovascular disease. |
| Q36256231 | Anticardiolipin antibodies and ocular disease |
| Q61768913 | Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study |
| Q71787427 | Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro |
| Q33491466 | Anticardiolipin antibodies in HIV infection: association with cerebral perfusion defects as detected by 99mTc-HMPAO SPECT. |
| Q72164919 | Anticardiolipin antibodies in children and adolescents with insulin-dependent diabetes mellitus |
| Q47988430 | Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic events |
| Q33487732 | Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations |
| Q40549583 | Anticardiolipin antibodies in the polymyalgia rheumatica-temporal arteritis syndromes |
| Q79245648 | Anticardiolipin antibodies in various diseases in Taiwan: a retrospective analysis |
| Q48437611 | Anticardiolipin antibodies, a disease marker for ischemic cerebrovascular events in a younger patient population? |
| Q36166418 | Anticardiolipin antibody and Taiwanese chronic haemodialysis patients with recurrent vascular access thrombosis |
| Q71984959 | Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis |
| Q33566574 | Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia |
| Q35934717 | Antiphospholipid (Hughes) syndrome |
| Q33893371 | Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus |
| Q35177118 | Antiphospholipid Antibodies: Proposed Mechanisms of Action |
| Q55031370 | Antiphospholipid Antibody Induced by Nivolumab. |
| Q53615681 | Antiphospholipid and antisynthetase syndrome in a patient with polymyositis-rheumatoid arthritis overlap. |
| Q33566129 | Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? |
| Q33494474 | Antiphospholipid antibodies and ischaemic heart disease |
| Q48159962 | Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus |
| Q40506562 | Antiphospholipid antibodies and the antiphospholipid syndrome |
| Q37358421 | Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein |
| Q37744837 | Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. |
| Q73722705 | Antiphospholipid antibodies in children |
| Q73069261 | Antiphospholipid antibodies in healthy pregnant women |
| Q71940048 | Antiphospholipid antibodies in inflammatory bowel disease |
| Q33491163 | Antiphospholipid antibodies in paediatrics |
| Q73090825 | Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa |
| Q53979828 | Antiphospholipid antibodies, beta 2-glycoprotein I and thrombosis. |
| Q40583128 | Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying 'membrane stress syndrome' hypothesis |
| Q43931131 | Antiphospholipid antibodies--new insights into their specificity and clinical importance |
| Q33491626 | Antiphospholipid antibodies: specificity and pathophysiology |
| Q41819349 | Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis |
| Q71556228 | Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies |
| Q72187640 | Antiphospholipid antibody syndrome associated with microscotomata |
| Q99712595 | Antiphospholipid antibody syndrome with thrombotic splenic infarcts associated with acute cytomegalovirus infection |
| Q41713369 | Antiphospholipid antibody syndrome: current concepts |
| Q40583137 | Antiphospholipid antibody testing in patients with pregnancy loss |
| Q28195585 | Antiphospholipid syndrome |
| Q38841201 | Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria? |
| Q33499667 | Antiphospholipid syndrome and the skin |
| Q58034664 | Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome |
| Q43846747 | Antiphospholipid syndrome associated with intestinal amoebiasis |
| Q73282316 | Antiphospholipid syndrome during chronic myelomonocytic leukemia |
| Q53349053 | Antiphospholipid syndrome in SLE. |
| Q35099505 | Antiphospholipid syndrome: an overview. |
| Q34331685 | Antiphospholipid syndrome; its implication in cardiovascular diseases: a review |
| Q36337350 | Antiphospholipid-related chorea. |
| Q71517613 | Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis |
| Q41157164 | Antithrombotic and fibrinolytic factors. A review |
| Q43949716 | Apathetic Graves' disease and acquired hemophilia due to factor VIIIc antibody |
| Q44282808 | Arterial thrombosis in a previously healthy woman |
| Q37638876 | Aseptic necrosis at multiple localisations in a lupus patient with lymphoma |
| Q40558527 | Assays for detection of antiphospholipid antibodies |
| Q73251576 | Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease |
| Q40848303 | Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. |
| Q72554533 | Association of antiphospholipid antibodies with systemic lupus erythematosus in a child presenting with chorea: a case report |
| Q33489338 | Association of cerebral vasculitis with a lupus anticoagulant. A case with brain pathology |
| Q36307423 | Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study |
| Q36332517 | Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus |
| Q35171667 | Autoimmune disease as a cause of reproductive failure |
| Q41418252 | Autoimmunity and reproduction |
| Q48115169 | Brain reactive autoantibodies and cognitive impairment in systemic lupus erythematosus |
| Q34307190 | Brain single-photon emission tomography with 99mTc-HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations |
| Q34219323 | Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies |
| Q33536795 | Catastrophic antiphospholipid syndromes in systemic lupus erythematosus |
| Q48158073 | Cerebral lupus |
| Q33564596 | Cerebral occlusive vasculopathy in systemic lupus erythematosus and speculation on the part played by complement |
| Q41270539 | Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options |
| Q36734776 | Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). |
| Q33501021 | Chronic myelomonocytic leukemia in a patient with antiphospholipid syndrome: first case report |
| Q72717182 | Circulating autoimmune antibodies may be responsible for implantation failure in in vitro fertilization |
| Q33349144 | Circulating lupus coagulation inhibitor in two sisters, one with disseminated lupus erythematosus and the other with immunologic thrombocytopenic purpura |
| Q33494911 | Clinical analysis of 125 patients with the lupus anticoagulant |
| Q41367920 | Clinical biochemistry of pregnancy |
| Q34196159 | Clinical evaluation of hypercoagulable states |
| Q40835346 | Clinical implications of laboratory testing for the thrombophilic disorders |
| Q33370780 | Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? |
| Q33496508 | Clinical manifestations and management of the antiphospholipid syndrome |
| Q33505107 | Clinical significance of lupus anticoagulants in children |
| Q33496557 | Clinical significance of phospholipid-dependent anti-beta 2-glycoprotein I (beta 2-GPI) antibodies in systemic lupus erythematosus |
| Q33365787 | Clinicohematologic spectrum in patients with lupus anticoagulant. |
| Q35625220 | Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus |
| Q37314013 | Cognitive dysfunction in systemic lupus erythematosus: past, present, and future |
| Q73748107 | Correction for age of anticardiolipin antibodies cut-off points |
| Q33495018 | Demonstration of antiphospholipid antibody heterogeneity by phospholipid column chromatography and salt gradient elution techniques |
| Q41744362 | Dermatologic findings associated with antiphospholipid antibody syndrome |
| Q40637281 | Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism |
| Q33384872 | Development of paroxysmal nocturnal haemoglobinuria in systemic lupus erythematosus: an unusual cause of portal vein thrombosis |
| Q40387503 | Diagnosis and management of antiphospholipid syndrome |
| Q38186995 | Diagnosis and management of neuropsychiatric SLE. |
| Q33339824 | Diagnosis and management of patients with the antiphospholipid syndrome |
| Q31166031 | Diagnosis and pathogenesis of CNS lupus |
| Q34985905 | Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature |
| Q33886973 | Diagnostic evaluation of stroke |
| Q33494551 | Different manifestations of the antiphospholipid antibody syndrome in a family with systemic lupus erythematosus |
| Q73163209 | Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome |
| Q73128263 | Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes |
| Q35029916 | Dyslipidaemia in rheumatological autoimmune diseases |
| Q53190790 | Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. |
| Q41524233 | Effects of sustained i.c.v. infusion of lupus CSF and autoantibodies on behavioral phenotype and neuronal calcium signaling |
| Q43080330 | Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies |
| Q44892012 | Epitope mapping studies of antiphospholipid antibodies and beta 2-GPI using synthetic peptides |
| Q50156154 | Evaluation of abdominal pain in systemic lupus erythematosus |
| Q31933342 | Evaluation of patients with CNS involvement in SLE. |
| Q58709046 | Evaluation of serum uric acid level in systemic lupus erythematosus patients with normal and high pulmonary arterial hypertension |
| Q40467282 | Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management |
| Q35968911 | Evidence-based risk factors for postoperative deep vein thrombosis |
| Q35636977 | Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis |
| Q71843089 | Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies |
| Q78759683 | Fetal survival in the rat as affected by intrauterine injection of serum containing antiphospholipid antibodies |
| Q72177020 | Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy |
| Q33338791 | Foetal loss, liver necrosis and acute lupus erythematosus in a patient with antiphospholipid antibody syndrome |
| Q35821557 | For the want of an heir: the obstetrical history of Queen Anne |
| Q61405667 | From antiphospholipid syndrome to antibody-mediated thrombosis |
| Q36503072 | From normal to pathological hemostasis. |
| Q40761044 | Gastrointestinal hemorrhage and intestinal ischemia associated with anticardiolipin antibodies |
| Q36807470 | Genetic risk factors for thrombosis in systemic lupus erythematosus |
| Q33723529 | Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus |
| Q33421876 | Haematological manifestations of lupus |
| Q60042738 | Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I |
| Q33498890 | Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome |
| Q47959608 | Hemolysis, hemorrhage, headache, and hidden abortion: imaging findings in antiphospholipid syndrome |
| Q33493322 | Hepatic infarction in a pregnant patient with the 'primary' antiphospholipid syndrome |
| Q73690703 | High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome |
| Q35549772 | How to treat women with antiphospholipid antibodies in pregnancy? |
| Q39946768 | Humoral mechanisms of atherogenesis. |
| Q36233246 | Hypercoagulability in Vascular Surgery Patients |
| Q35179215 | Hypercoagulable state testing and malignancy screening following venous thromboembolic events |
| Q78081224 | Hypercoagulable states in patients with retinal venous occlusion |
| Q36783002 | Hypercoagulable states. Their causes and management |
| Q36157442 | Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity |
| Q53804346 | Identification of antiphospholipid antibodies in systemic lupus erythematosus on thin layer chromatography and immunostaining |
| Q67562727 | Identification of persons with high risk of venous thrombosis |
| Q57089710 | Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders |
| Q47796229 | Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients |
| Q44996719 | Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus |
| Q28193686 | Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events |
| Q34424615 | Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies |
| Q40834203 | Inflammatory ulcers |
| Q33377847 | Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients |
| Q33564647 | Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum |
| Q24672569 | Interactions and molecular structure of cardiolipin and β2-glycoprotein 1 (β2-GP1) |
| Q31942717 | Internuclear ophthalmoplegia in systemic lupus erythematosus |
| Q40864029 | Ischemic stroke in the young: evaluation and age comparison of patients six months to thirty-nine years |
| Q40544886 | Laboratory diagnosis of antiphospholipid syndromes. |
| Q41024567 | Laboratory diagnosis of hemorrhagic and thrombotic disorders. |
| Q35099172 | Laboratory diagnosis of the antiphospholipid syndrome |
| Q45862435 | Lack of correlation between anticardiolipin antibodies and peripheral autonomic nerve involvement in systemic lupus erythematosus |
| Q34436477 | Leg ulcer diagnosis and management |
| Q47891074 | Lipid interactions with human antiphospholipid antibody, beta 2-glycoprotein 1, and normal human IgG using the fluorescent probes NBD-PE and DPH. |
| Q74397230 | Longer aPTT values in healthy children than in adults: no single cause |
| Q33356515 | Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study |
| Q45753856 | Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia |
| Q33488491 | Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report |
| Q51680254 | Lupus anticoagulant, paramyotonia congenita and pregnancy |
| Q40735872 | Lupus anticoagulant: a potential risk factor for complication following percutaneous transluminal coronary angioplasty |
| Q58482181 | Lupus erythematosus with antiphospholipid syndrome and erythema multiforme-like lesions |
| Q46945978 | Lupus in children in Tunisia |
| Q33376538 | Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies |
| Q28188666 | Management of thrombosis in antiphospholipid antibody syndrome |
| Q45873306 | Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders |
| Q40474895 | Massive Lower Extremity Arterial Thrombosis and Acute Hepatic Insufficiency in a Young Adult with Premature Atherosclerosis Associated with Hyperlipoprotein(a)emia and Antiphospholipid Syndrome |
| Q37832196 | Maternal autoantibodies and pregnancy--I: The antiphospholipid antibody syndrome |
| Q37111561 | Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus |
| Q36070612 | Migraine and antiphospholipid antibodies |
| Q34352811 | Migraine and haemostasis |
| Q24633473 | Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant |
| Q33489236 | Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: Characterization and the induction of a secondary antiphospholipid syndrome |
| Q36951406 | Moyamoya syndrome associated with Sneddon's syndrome and antiphospholipid-protein antibodies |
| Q58696809 | Multimodal computed tomography-guided intravenous rtPA for aborted stroke in a HIV-infected young man: a case report |
| Q35104548 | Multiple autoantibodies associated with autoimmune reproductive failure |
| Q71112355 | Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry |
| Q33492946 | Neonatal thrombocytopenia and hidden maternal autoimmunity. |
| Q28193094 | Nephrological and obstetric complications of the antiphospholipid syndrome |
| Q34735687 | Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome |
| Q34250901 | Neuropsychiatric lupus |
| Q71933430 | Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests |
| Q33414595 | Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome |
| Q73069275 | Obstetric management of the high-risk lupus pregnancy |
| Q40998663 | Obstetric outcome in systemic lupus erythematosus |
| Q35535848 | Obstetrical implications of antiphospholipid antibodies |
| Q39225546 | Obstetrical outcome of pregnancy in patients with systemic Lupus erythematosus. A study of 60 cases |
| Q73267440 | Occurrence of anti-prothrombin and anti-beta2-glycoprotein I antibodies in patients with history of thrombosis |
| Q43568071 | Ocular features associated with anticardiolipin antibodies: a descriptive study |
| Q64248332 | Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL) |
| Q37888952 | Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review |
| Q48134177 | Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin |
| Q36960917 | Orthopedic involvement in antiphospholipid syndrome |
| Q34092352 | Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus |
| Q43926851 | Ovulation induction, lupus and antiphospholipids |
| Q33498327 | Pathogenesis and treatment of the antiphospholipid antibody syndrome |
| Q40875971 | Pathology and the nine ages of rheumatism. Advances in knowledge of the connective tissue diseases |
| Q36054832 | Pathology of lupus nephritis |
| Q40664381 | Patient with both lupus anticoagulant and acute disseminated encephalomyelitis |
| Q44088329 | Peripheral neuropathy in pediatric systemic lupus erythematosus |
| Q28367919 | Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus |
| Q33739280 | Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients. |
| Q67824075 | Platelet Function and Plasma Factors in Connective Tissue Disorders |
| Q47719673 | Platelet activation and turnover in the primary antiphospholipid syndrome |
| Q40582616 | Platelet factors predisposing to arterial thrombosis |
| Q58957193 | Platelet glycoprotein Ibα polymorphisms and function evaluated by the platelet function analyzer PFA-100 in patients with lupus anticoagulant: the association with thromboembolic disease |
| Q50571950 | Polarization toward Th1-type response in active, but not in inactive, lupus inhibits late allergic rhinitis in lupus-prone female NZB×NZWF(1) mice. |
| Q73332373 | Polyclonal anticardiolipin antibodies purified from sera of patients with active systemic lupus erythematosus induce apoptosis of the cultured glomerular mesangial cells |
| Q34156600 | Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute Dynamic Registry |
| Q33382838 | Postpartum spontaneous colonic perforation due to antiphospholipid syndrome |
| Q33493247 | Pregnancy outcome in women with antiphospholipid antibodies |
| Q36806527 | Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus |
| Q36500737 | Presence of lupus anticoagulant in an asymptomatic Nigerian |
| Q33376853 | Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study |
| Q40651854 | Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies |
| Q73625286 | Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients |
| Q77849800 | Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses |
| Q43677862 | Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE). |
| Q47877215 | Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis |
| Q87342421 | Prevalence and pathology of vascular occlusive disease in the antiphospholipid syndromes |
| Q45871319 | Prevalence and prognostic significance of anticardiolipin antibodies in pregnancies complicated by human immunodeficiency virus-1 infection |
| Q72048474 | Prevalence and significance of anticardiolipin antibodies in Crohn's disease |
| Q33502832 | Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C. |
| Q50944728 | Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. |
| Q34166707 | Prevalence of anticardiolipin antibodies in pregnancies with history of repeated miscarriages |
| Q72355315 | Prevalence of antiphospholipid antibodies in nephropathies not due to systemic lupus erythematosus |
| Q36008969 | Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study |
| Q67470055 | Previous Pregnancy Outcome Is an Important Determinant of Subsequent Pregnancy Outcome in Women With Systemic Lupus Erythematosus |
| Q34674429 | Primary anti-phospholipid antibody syndrome (APS): current concepts |
| Q33488831 | Primary antiphospholipid syndrome associated with postoperative primary adrenal failure |
| Q73694791 | Primary antiphospholipid syndrome in stroke in the young |
| Q52883370 | Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS). |
| Q40983564 | Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant |
| Q41197517 | Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis |
| Q40558476 | Protein C pathway, antiphospholipid antibodies and thrombosis |
| Q58490859 | Pulmonary hypertension in a seventeen-year-old boy |
| Q77903286 | Pulmonary manifestations of systemic lupus erythematosus |
| Q50582731 | Pure red cell aplasia and primary antiphospholipid syndrome: a unique association. |
| Q81150257 | Rash, drug hypersensitivity, and autoimmunity in a 20-year-old woman |
| Q33363443 | Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus |
| Q35443320 | Recent advances in understanding clotting and evaluating patients with recurrent thrombosis |
| Q33329880 | Recognition and management of preoperative risk |
| Q58861357 | Recurrent Thrombosis in Patients with Deep Vein Thrombosis and/or Venous Thromboembolism Associated with Anticardiolipin Antibodies |
| Q73835437 | Relation between left ventricular and/or left atrial thrombus and anticardiolipin antibodies in patients with acute myocardial infarction |
| Q40986119 | Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome. |
| Q37339048 | Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. |
| Q33493550 | Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients |
| Q54161216 | Resistance to activated protein C in healthy women taking oral contraceptives. |
| Q39724183 | Retinal arterial occlusion associated with resistance to activated protein C |
| Q38679687 | Retinal vasculitis in systemic lupus erythematosus: an indication of active disease |
| Q28166964 | Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment |
| Q33503504 | Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus |
| Q36310765 | Rheumatic disease among Oklahoma tribal populations: a cross-sectional study |
| Q33871715 | Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort |
| Q43627667 | Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease |
| Q41939439 | Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. |
| Q37007898 | Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study |
| Q36065912 | Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus |
| Q71009161 | Selection and use of laboratory tests in the rheumatic diseases |
| Q40733320 | Serologic tests for connective tissue diseases and the primary vasculitides. |
| Q52898719 | Serological characteristics of systemic lupus erythematosus from a hospital-based rheumatology clinic in Kuwait. |
| Q33488994 | Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations |
| Q57089556 | Significance of anticardiolipin and anti‐β2‐glycoprotein I antibodies in lupus nephritis |
| Q44957594 | Single nucleotide polymorphisms in the coding region of the apolipoprotein H (beta2-glycoprotein I) gene and their correlation with the protein polymorphism, anti-beta2glycoprotein I antibodies and cardiolipin binding: description of novel haplotype |
| Q72897278 | Sneddon's syndrome and phospholipid antibodies |
| Q33372491 | Specificities of platelet autoantibodies and platelet activation in lupus anticoagulant patients: a relation to their history of thromboembolic disease |
| Q33493445 | Spectrum of clinical manifestations of antiphospholipid antibodies in childhood and adolescence |
| Q33330250 | Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome |
| Q33494866 | Splenic infarction associated with anticardiolipin antibodies in a patient with acquired immunodeficiency syndrome |
| Q43275855 | Statins for the treatment of antiphospholipid syndrome? |
| Q35189292 | Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. |
| Q41281744 | Superficial migratory thrombophlebitis in a patient with reversible protein C deficiency and anticardiolipin antibodies |
| Q54440278 | Superficial thrombophlebitis and anticardiolipin antibodies--report of association. |
| Q35934706 | Systemic lupus erythematosus and related diseases |
| Q37367425 | Systemic lupus erythematosus and the obstetrical patient--implications for the anaesthetist |
| Q41669597 | Systemic lupus erythematosus in India |
| Q46443879 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients |
| Q33374070 | Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor |
| Q28344247 | Systemic lupus erythematosus presenting earlier as retinal vaso-occlusion |
| Q40371891 | Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction |
| Q33329023 | TTP-Like syndrome in a 44-year-old woman with SLE and nephritis |
| Q58004012 | Testing strategies for diagnosing lupus anticoagulant: Decision analysis |
| Q35177111 | The Effect of Systemic Lupus Erythematosus on Pregnancy and Pregnancy Outcome |
| Q50068482 | The anti-phospholipid syndrome |
| Q33374702 | The antiphospholipid antibody syndrome in the emergency department setting — Livedo reticularis and recurrent venous thrombosis |
| Q40977408 | The antiphospholipid-protein syndrome |
| Q45061328 | The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus |
| Q33393481 | The autoimmunity conundrum: clotting or inflammation |
| Q40804890 | The clinical implications of autoantibody detection in rheumatology. |
| Q34151618 | The clinical significance of antiphospholipid antibodies in patients without autoimmune disease |
| Q28072610 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus |
| Q77925672 | The clinico-ophthalmological spectrum of antiphospholipid syndrome |
| Q40446708 | The effect of comorbid conditions on hemodialysis access patency |
| Q28186810 | The epidemiology of the antiphospholipid syndrome: who is at risk? |
| Q48220131 | The etiology of psychiatric symptoms in patients with systemic lupus erythematosus. |
| Q37179099 | The impact of inherited thrombophilia on surgery: a factor to consider before transplantation? |
| Q37186025 | The impact of positive acquired thrombophilia serology on ultrasound, obstetric outcome and the placenta in a low-risk primigravid population |
| Q77291965 | The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events |
| Q36229639 | The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies |
| Q36434130 | The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis |
| Q33383811 | The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant |
| Q81260615 | The prevalence of lupus anticoagulant in normal pregnancy and in women with recurrent fetal loss--recommendations for laboratory testing for lupus anticoagulant |
| Q26765406 | The role of anti-phospholipid antibodies in autoimmune reproductive failure |
| Q35966558 | The role of antiphospholipid antibodies in stroke. |
| Q41066141 | The role of beta 2-glycoprotein I in the antiphospholipid syndrome |
| Q35653937 | The role of prostaglandins in obstetrical disorders |
| Q35199884 | The use of apheresis in immune renal disorders |
| Q43487024 | Thromboembolism in paediatric lupus patients |
| Q34043661 | Thrombophilia in pregnancy |
| Q36679115 | Thrombophilia: how far should a clotter be investigated? |
| Q36147794 | Thrombosis in systemic lupus erythematosus: a review article |
| Q46525988 | Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. |
| Q51104155 | Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. |
| Q33360771 | Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies |
| Q41475203 | Thrombotic syndromes and autoimmune diseases |
| Q33939249 | Transient visual symptoms in systemic lupus erythematosus and antiphospholipid syndrome |
| Q42062283 | Transmission of lupus anticoagulant by allogeneic stem cell transplantation |
| Q78814998 | Treatment of lupus nephritis |
| Q41197504 | Treatment of neurologic complications of antiphospholipid antibody syndrome |
| Q71992286 | Treatment of the antiphospholipid syndrome |
| Q63681605 | Trousseau's syndrome with nonbacterial thrombotic endocarditis: Pathogenic role of antiphospholipid syndrome |
| Q39150632 | Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. |
| Q41467405 | Unusual causes of mesenteric ischemia |
| Q50927330 | Valve excrescences: prevalence, evolution and risk for cardioembolism. |
| Q77492467 | Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies? |
| Q40519209 | Vasculitis associated with antiphospholipid syndrome |
| Q41529189 | Vasculitis associated with connective tissue disease |
| Q33566329 | Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation |
| Q52477266 | [Antiphospholipid antibodies (aPL): detection and clinical significance]. |
| Q72936591 | [Multiple autoimmune syndrome] |
| Q77467515 | [Neurological manifestations of antiphospholipid syndrome] |
| Q73960298 | [Prevalence of antiphospholipid syndrome in patients under 65 years of age with acute myocardial infarction] |
| Q74800363 | [Right atrial myxoma in a patient with antiphospholipid antibodies] |
| Q72591857 | [Selective IgA deficiency and antiphospholipid syndrome] |
| Q72441735 | [What criteria for the diagnosis of antiphospholipid syndrome?] |
| Q41375519 | β2-Glycoprotein I-Dependent Anti-Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus. |
Search more.